Lisbon, Portugal - May 8 - 9, 2024

Alejandro Ocampo

Assistant Professor Department of Biomedical Sciences University of Lausanne Switzerland

Alejandro Ocampo obtained his PhD in 2012 from the University of Miami. Between 2013 and 2017, he carried out a postdoc with Juan Carlos Izpisua-Belmonte where he developed a novel technology to prevent the transmission of mitochondrial diseases and demonstrated the amelioration of age-associated hallmarks by partial cellular reprogramming. In August 2018, he joined the University of Lausanne in Switzerland where he continues his research on aging and cellular reprogramming.

“Overcoming the dark side of in vivo reprogramming”

In vivo reprogramming has recently emerged as one of the most promising strategies for targeting aging, attracting great interest from both academic and private sectors. Nevertheless, despite its great potential, significant translational barriers such as safety and gene delivery will need to be overcome for the clinical application of reprogramming to humans. In this line, we have recently demonstrated that hepatic and intestinal failure lead to high mortality upon continuous induction of in vivo reprogramming. In addition, we have generated novel mouse strains that avoid the reprogramming of these organs allowing for more extensive in vivo reprogramming protocols. Lastly, we have shown that improvement of age-associate phenotypes and lifespan extension can be achieved by chemical induced partial reprogramming using small molecules, opening a path towards future clinical applications of cellular reprogramming.

Sign up to receive Longevity Med Summit
and updates